Irfan A Asangani
Overview
Explore the profile of Irfan A Asangani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
5381
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schwab A, Siddiqui M, Ramesh V, Gollavilli P, Turtos A, Moller S, et al.
Cell Death Differ
. 2024 Nov;
PMID: 39567724
Despite recent treatment advances, non-small cell lung cancer (NSCLC) remains one of the leading causes of cancer-related deaths worldwide, and therefore it necessitates the exploration of new therapy options. One...
2.
Parolia A, Eyunni S, Verma B, Young E, Liu Y, Liu L, et al.
Nat Genet
. 2024 Sep;
56(10):2132-2143.
PMID: 39251788
Androgen receptor (AR) is a ligand-responsive transcription factor that drives terminal differentiation of the prostatic luminal epithelia. By contrast, in tumors originating from these cells, AR chromatin occupancy is extensively...
3.
Wang X, Qiao Y, Asangani I, Ateeq B, Poliakov A, Cieslik M, et al.
Cancer Cell
. 2024 Aug;
42(8):1471.
PMID: 39137731
No abstract available.
4.
Parolia A, Eyunni S, Verma B, Young E, Liu L, George J, et al.
bioRxiv
. 2024 Mar;
PMID: 38464251
The androgen receptor (AR) is a ligand-responsive transcription factor that binds at enhancers to drive terminal differentiation of the prostatic luminal epithelia. By contrast, in tumors originating from these cells,...
5.
Katsuda T, Sussman J, Ito K, Katznelson A, Yuan S, Takenaka N, et al.
Nat Commun
. 2024 Feb;
15(1):1761.
PMID: 38409161
Tissue damage elicits cell fate switching through a process called metaplasia, but how the starting cell fate is silenced and the new cell fate is activated has not been investigated...
6.
Rasool R, OConnor C, Das C, Alhusayan M, Verma B, Islam S, et al.
Nat Commun
. 2023 Aug;
14(1):5253.
PMID: 37644036
Loss of the tumor suppressive activity of the protein phosphatase 2A (PP2A) is associated with cancer, but the underlying molecular mechanisms are unclear. PP2A holoenzyme comprises a heterodimeric core, a...
7.
Walter D, Gladstein A, Doerig K, Natesan R, Baskaran S, Gudiel A, et al.
Commun Biol
. 2023 Mar;
6(1):255.
PMID: 36899051
SETD2 is a tumor suppressor that is frequently inactivated in several cancer types. The mechanisms through which SETD2 inactivation promotes cancer are unclear, and whether targetable vulnerabilities exist in these...
8.
Katsuda T, Sussman J, Ito K, Katznelson A, Yuan S, Li J, et al.
bioRxiv
. 2023 Feb;
PMID: 36824858
Tissue damage elicits cell fate switching through a process called metaplasia, but how the starting cell fate is silenced and the new cell fate is activated has not been investigated...
9.
Deng Q, Natesan R, Cidre-Aranaz F, Arif S, Liu Y, Rasool R, et al.
Cell Rep
. 2022 Jun;
39(11):110971.
PMID: 35705030
Ewing sarcoma (EwS) is a highly aggressive tumor of bone and soft tissues that mostly affects children and adolescents. The pathognomonic oncofusion EWSR1::FLI1 transcription factor drives EwS by orchestrating an...
10.
Penning T, Asangani I, Sprenger C, Plymate S
Cancer Drug Resist
. 2022 May;
3(4):912-929.
PMID: 35582223
Castration-resistant prostate cancer is the lethal form of prostate cancer and most commonly remains dependent on androgen receptor (AR) signaling. Current therapies use AR signaling inhibitors (ARSI) exemplified by abiraterone...